Zydus Lifesciences and Formycon announced a major regulatory milestone for their proposed cancer treatment, FYB206. The US Food and Drug Administration accepted the companies’ biologics license application for review. The Keytruda Biosimilar candidate targets the market for pembrolizumab, a widely used immunotherapy medicine. The announcement marks an important step toward potential competition in a high-value oncology market.
Keytruda Biosimilar Advances Through a Streamlined Development Pathway
The companies announced the milestone on October 13, 2026, describing it as the first publicly announced FDA review acceptance for a proposed Keytruda biosimilar. The application was submitted during the third quarter of 2026. The FDA aims to complete its review within the applicable regulatory timeline, potentially enabling a decision during the third quarter of 2027. Acceptance for review does not mean the product has been approved for sale.
FYB206 blocks the PD-1 immune checkpoint pathway through pembrolizumab, the same active ingredient used in Keytruda. This pathway helps regulate immune responses, and its inhibition can enable immune cells to attack certain cancers. The Keytruda Biosimilar development programme followed a pathway agreed with the FDA, using analytical comparisons and pharmacokinetic evidence. The companies did not conduct a comparative Phase III efficacy trial for this candidate.
The development strategy could reduce research costs and shorten development timelines compared with more extensive clinical programmes. Formycon reported that the pivotal pharmacokinetic study demonstrated equivalence to the reference medicine and that clinical development concluded in July 2026. Keytruda generated approximately $31.7 billion in worldwide sales during 2025, highlighting the commercial significance of potential future competition. However, market entry will depend on regulatory approval and the resolution of applicable intellectual property issues.
Under their licensing agreement, Formycon is responsible for development, regulatory submissions, manufacturing, and supply. Zydus holds exclusive commercialisation rights in the United States and Canada, subject to approval. The companies have also submitted a regulatory dossier to Health Canada. The Keytruda Biosimilar programme could create a significant commercial opportunity, although actual pricing, reimbursement, and patient access remain uncertain.
For patients, additional competition could eventually improve treatment affordability and broaden access to immunotherapy. However, neither approval nor lower treatment costs can be guaranteed at this stage. The Keytruda Biosimilar application now enters regulatory assessment, making the FDA’s eventual decision an important milestone. The outcome could influence future biosimilar development strategies across the global oncology industry.
